Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2009 March;34(1) > Minerva Endocrinologica 2009 March;34(1):57-69

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Endocrinologica 2009 March;34(1):57-69

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases

De Klerk J. M. H., Oyen W. J. G.

Department of Nuclear Medicine Meander Medical Center, Amersfoort The Netherlands


PDF


Radioiodine plays an important role in the treatment of thyroid cancer. It is used for thyroid remnant ablation as well as for treatment of metastatic disease. Despite the fact that it is used all over the world for these indications, the exact administered dose is still a subject for discussion. Two methods are widely available: the so-called fixed empiric method and the dosimetric one. This review will highlight the aspects of radioiodine in treatment of thyroid cancer and discuss the advantages and disadvantages of the several methods for the calculation of the administered dose.

top of page